Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol. 2018;31(1):35.
PubMed
Google Scholar
Alavian SM, Aalaei-Andabili SH. Lack of knowledge about hepatitis C infection rates among patients with inherited coagulation disorders in countries under the Eastern Mediterranean Region Office of WHO (EMRO): a meta-analysis. Hepat Mon. 2012;12(4):244.
Article
Google Scholar
Walsh C, Workowski K, Terrault N, Sax P, Cohen A, Bowlus C, et al. Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017;23(2):198–206.
Article
CAS
Google Scholar
Tagliaferri A, Rivolta G, Iorio A, Oliovecchio E, Mancuso M, Morfini M, et al. Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia. 2010;16(3):437–46.
CAS
PubMed
Google Scholar
Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL 4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal. 2017;31(4):e22063.
Article
Google Scholar
Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother. 2008;61(6):1191–200.
Article
CAS
Google Scholar
Lee HW, Yoo KY, Won JW, Kim HJ. Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-naïve or treatment-experienced. Gut Liver. 2017;11(5):721.
Article
CAS
Google Scholar
Perazzo H, Castro R, Luz PM, Banholi M, Goldenzon RV, Cardoso SW, et al. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. Bull World Health Organ. 2020;98(3):188.
Article
Google Scholar
World Health Organization. Global health sector strategy on viral hepatitis 2016–2021 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1.
Alavian SM, Hajarizadeh B, Lankarani KB, Sharafi H, Daryani NE, Merat S, et al. Recommendations for the clinical management of hepatitis C in Iran: a consensus-based national guideline. Hepat Mon. 2016;16(8):e40959.
Article
Google Scholar
Dorgalaleh A, Dadashizadeh G, Bamedi T. Hemophilia in Iran. Hematology. 2016;21(5):300–10.
Article
CAS
Google Scholar
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45–57.
Article
Google Scholar
Alavian SM, Sharafi H. Update on recommendations for the clinical management of hepatitis C in Iran 2017. Hepat Mon. 2017;17(11):4.
Article
Google Scholar
European Association for the Study of the Liver 2017. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.
Article
Google Scholar
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–94.
Article
Google Scholar
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
Article
Google Scholar
Mancuso ME, Linari S, Santagostino E, Bartolozzi D, D’Ambrosio R, Borghi M, et al. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: a multicenter study. Liver Int. 2020;40(5):1062–8.
Article
CAS
Google Scholar
Keshvari M, Alavian SM, Behnava B, Pouryasin A, Sharafi H. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. J Res Med Sci Off J Isfahan Univ Med Sci. 2016;21:72.
Google Scholar
Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination–A path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665–6.
Article
Google Scholar
Hepatitis C. guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–92.
Article
Google Scholar
Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, et al. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS ONE. 2019;14(4):70214795.
Article
Google Scholar
D’Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379–87.
Article
CAS
Google Scholar
Kwo P, Gane EJ, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164–75.
Article
CAS
Google Scholar
Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of ledipasvir and sofosbuvir for treatment of hepatitis C virus genotype 1 infection: systematic review and meta-analysis. Ann Hepatol. 2017;16(2):188–97.
Article
Google Scholar
Zeng Q-L, Xu G-H, Zhang J-Y, Li W, Zhang D-W, Li Z-Q, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. J Hepatol. 2017;66(6):1123–9.
Article
CAS
Google Scholar
Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepat Mon. 2017;17(1):1.
Google Scholar
Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of generic sofosbuvir/ledipasvir fixed-dose combination in Iranian patients with chronic hepatitis C virus infection. Hepat Mon. 2017. https://doi.org/10.5812/hepatmon.12216.
Article
Google Scholar
Sharafi H, Alavian SH, Behnava B, Rezaee-Zavareh MS, Nikbin M, Alavian SM. Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: a cohort study. Casp J Intern Med. 2020;11(1):41.
Google Scholar
Fransen L, D’hondt P, Bielen R, Van den Ende N, Robaeys G, Peerlinck K, et al. Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: a single-centre experience. Haemophilia. 2019;25(6):1028–34.
Article
CAS
Google Scholar
Guedes TP, Garrido M, Morais S, Pedroto I. High rate of SVR with DAA in haemophiliacs with HCV infection: three decades of follow-up of a Portuguese single-centre cohort. Liver Intl: Off J Int Assoc Study Liver. 2020;40:1783–4.
Article
Google Scholar
Nagao A, Hanabusa H. Brief report: the impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. JAIDS J Acquir Immune Defic Syndr. 2017;74(4):418–22.
Article
CAS
Google Scholar
Stedman C, Hyland R, Ding X, Pang P, McHutchison J, Gane E. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016;22(2):214–7.
Article
CAS
Google Scholar
Uemura H, Tsukada K, Mizushima D, Aoki T, Watanabe K, Kinai E, et al. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS ONE. 2017;12(10):e0186255.
Article
Google Scholar
Xiao H, Chen J, Wang J, Li J, Yang F, Lu H. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine. 2019;98(30):e16524.
Article
CAS
Google Scholar
Kowdley KV, Nelson DR, Lalezari JP, Box T, Gitlin N, Poleynard G, et al. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. Liver Int Off J Int Assoc Study Liver. 2016;36(11):1611–8.
CAS
Google Scholar
Karimi-Sari H, Rezaee-Zavareh MS. COVID-19 and viral hepatitis elimination programs: Are we stepping backward? Liver Int. 2020;40(8):2042.
Article
CAS
Google Scholar
Gregory C, Rino G, Richard G, Ghazinyan H, Dokmeci K, Tatsuo K, et al. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14(4):415–28.
Article
Google Scholar